Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
2011

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis

Sample size: 74 publication Evidence: moderate

Author Information

Author(s): Waschbisch Anne, Atiya Monika, Linker Ralf A., Potapov Sergej, Schwab Stefan, Derfuss Tobias, Kleinschnitz Christoph

Primary Institution: Friedrich-Alexander University, Erlangen-Nürnberg, Germany

Hypothesis

Does glatiramer acetate treatment restore the expression of deregulated microRNAs in patients with relapsing-remitting multiple sclerosis?

Conclusion

Glatiramer acetate treatment appears to normalize the expression of certain microRNAs in patients with relapsing-remitting multiple sclerosis.

Supporting Evidence

  • Four microRNAs were found to be aberrantly expressed in patients with relapsing-remitting multiple sclerosis compared to healthy controls.
  • Expression of miR-146a and miR-142-3p was significantly lower in glatiramer acetate treated patients.
  • The study analyzed the expression of five selected microRNAs in peripheral blood mononuclear cells.
  • Receiver operator characteristic curves indicated low discriminatory power for individual miRNAs.
  • The combination of certain miRNAs yielded a sensitivity of 77.8% and specificity of 88.0% in predicting disease.

Takeaway

This study found that a treatment called glatiramer acetate helps fix the levels of certain tiny molecules in the blood that are messed up in people with a disease called multiple sclerosis.

Methodology

The expression of selected microRNAs was analyzed in peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis and healthy controls using real-time PCR.

Potential Biases

Potential confounders include differences in age and disease duration among treatment groups.

Limitations

The study population was relatively active with a high percentage of patients experiencing recent relapses, which may influence miRNA expression.

Participant Demographics

Patients included 74 individuals with relapsing-remitting multiple sclerosis and 32 healthy controls, predominantly of Caucasian origin.

Statistical Information

P-Value

p=0.003; p=0.028

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0024604

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication